Preferences help
enabled [disable] Abstract
Number of results
2018 | 104 | 400-410
Article title

Eliminating side effects of pain therapies

Title variants
Languages of publication
Pain is a very serious problem associated with many types of health conditions. Unfortunately, patients suffering from intense pain often give up or cut down on taking analgesics because of side effects of such treatment. New generation drugs create an opportunity for supporting therapies effectively. Persistent constipation is one of the more acute side effects of administration of opioids. This article gives an extensive coverage of the PAMORA group of drugs that eliminate opioid-induced constipation. It also proposes future directions for contemporary studies on the subject and other feasible therapeutic applications for this group of medicines. The molecule developed under the POIG.01.04.00-14-213/12 project “New intestinal drug for control of side effects of opioid therapies” is one of the prospects. [The project] researched structures based on opioid peptide analogs behaving like opioid antagonists vs. intestinal μ receptors. In addition, [the structures] feature properties that can be used in oncological therapies because they inhibit growth of malignant cells. The structures are being tested on animal models.
Physical description
  • Mossakowski Medical Research Centre Polish Academy of Science, Laboratory of Chemical Synthesis, 5 A. Pawińskiego Str., 02-106 Warszawa, Poland
  • Instytut Homeostazy Sp. z o.o., 26/7 Lipska Str., 03-908 Warszawa, Poland
  • Medical University of Lodz, Faculty of Medicine, Department of Biochemistry, 6/8 Mazowiecka Str., 92-215 Łódź, Poland
  • Mossakowski Medical Research Centre Polish Academy of Science, Toxicology Research Laboratory, 5 A. Pawińskiego Str., 02-106 Warszawa, Poland
  • [1] Cheung CW, Qiu Q, Choi SW, et al. Chronic opioid therapy for chronic non-cancer pain: a review and comparison of treatment guidelines. Pain Physician. 2014; 17(5): 401-414.
  • [2] Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA. 2016; 315(15): 1624-1645.
  • [3] Sobanski P, Krajnik M, Shaqura M, et al. The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue. Heart Vessels. 2014; 29(6): 855-863.
  • [4] Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014; 2(1): 17-21.
  • [5] Peng J, Sarkar S, Chang SL. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend. 2012; 124(3): 223-228.
  • [6] Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013; 15(9): 344.
  • [7] Abramowitz L, Beziaud N, Labreze L, et al. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013; 16(12): 1423-1433.
  • [8] Hooten W, Lamer T, Twyner C. Opioid-induced hyperalgesia in community-dwelling adults with chronic pain. Pain. 2015; 156: 1145-1152.
  • [9] Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10 :113-130.
  • [10] Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008; 11(2): S133-S153.
  • [11] Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Physician. 2011; 14(4): E343-E360.
  • [12] Kalso E, Edwards J, Moore R, McQuay H. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 112: 372-380.
  • [13] Tack J, Corsetti M. Naloxegol for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol. 2014; 8: 855-861.
  • [14] Bell T, Panchal S, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (probe 1). Pain Med. 2009; 10: 35-42.
  • [15] Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014: ID141737.
  • [16] Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008; 27(12): 1224-1232.
  • [17] Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182(5A suppl): 11S-18S.
  • [18] Camilleri M, Drossman D, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroent Motil. 2014; 26: 1386-1395.
  • [19] Coyne K, Locasale R, Datto C, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014; 6: 269-281.
  • [20] Manara L, Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol. 1985; 25: 249-273.
  • [21] Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011; 106(5): 835-842.
  • [22] Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl. 2014; 2(1): 31-37.
  • [23] Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015; 16(12): 2324-2337.
  • [24] Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016; 150(6): 1393-1407
  • [25] Brenner DM, Stern E, Cash BD. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep. 2017; 19(3): 12.
  • [26] Verhaak P, Kerssens J, Dekker J, et al. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain. 1998; 77: 231-239.
  • [27] Mansfield K, Sim J, Jordan J, Jordan K. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain. 2015; 157: 55-64.
  • [28] Benyamin R, Trescot A, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008; 11: S105-S120.
  • [29] Oosten AW, Oldenmenger WH, Mathijssen RH, et al. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015; 16: 935-946.
  • [30] Leppert W. Emerging therapies for patients with symptoms of opioidinduced bowel dysfunction. Drug Des Devel Ther. 2015; 9: 2215-2231.
  • [31] Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011; 19(1): CD003448.
  • [32] Candy B, Jones L, Larkin PJ, et al. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015; 5: CD003448.
  • [33] Rosti G, Gatti A, Costantini A, et al. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci. 2010; 14(12): 1045-1050.
  • [34] Hale M, Wild J, Reddy J, et al. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallelgroup trials. Lancet Gastroenterol Hepatol. 2017; 2(8): 555-564.
  • [35] Siemens W, Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. Ther Clin Risk Manag. 2016; 12: 401-412.
  • [36] Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014; 370(25): 2387-2396.
  • [37] Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioidinduced constipation and analgesia. J Pain Symptom Manage. 2002; 23(1): 48-53.
  • [38] Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996; 10(2): 135-144.
  • [39] Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017; 18(12): 2350-2360.
  • [40] Pergolizzi JV Jr, Raffa RB, Pappagallo M, et al. Peripherally acting mu-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence. 2017; 11: 107-119.
  • [41] Armstrong SR, Campbell CB, Richardson CL, et al. The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386(6): 471-478.
  • [42] DiPetrillo L, Leigh-Pemberton R, Memisoglu A, et al. ALKS 37, A Novel, Peripherally-Restricted Opioid Receptor Antagonist, Demonstrates Efficacy in the Treatment of Opioid-Induced Bowel Dysfunction. Gastroenterol. 2011; 140(5): S-136.
  • [43] McKinnell RM, Armstrong SR, Beattie DT, et al. Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties. Bioorg Med Chem Lett. 2013; 23(14): 4210-4215.
  • [44] Yancey-Wrona JE, Raymond TJ, Mercer HK, et al. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice. Life Sci. 2009; 85(11-12): 413-420.
  • [45] Yancey-Wrona J, Dallaire B, Bilsky E, et al. 6beta-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Med. 2011; 12(12): 1727-1737.
  • [46] Yuan Y, Stevens DL, Braithwaite A, et al. 6beta-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists. Bioorg Med Chem Lett. 2012; 22(14): 4731-4734.
  • [47] Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the muopioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011; 63(4): 1001-1019.
  • [48] DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013; 344(3): 708-717.
  • [49] Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3) :e91577.
  • [50] Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013; 119(23): 4103-4110.
  • [51] Zylla D, Kuskowski MA, Gupta K, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014; 113(1): i109-i116.
  • [52] Janku F, Johnson LK, Karp DD, et al. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016; 27(11): 2032-2038.
  • [53] Li L, Setoguchi S, Cabral H, et al. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med. 2013; 273(5): 511-526.
  • [54] Carman WJ, Su S, Cook SF, et al. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011; 20(7): 754-762.
  • [55] Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010; 170(22): 1968-1976.
  • [56] Headrick JP, Pepe S, Peart JN. Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems. Curr Pharm Des. 2012; 18(37): 6090-6100.
  • [57] Reece AS, Hulse GK. Lifetime opiate exposure as an independent and interactive cardiovascular risk factor in males: a cross-sectional clinical study. Vasc Health Risk Manag. 2013; 9: 551-561.
  • [58] Tanaka K, Kersten JR, Riess ML. Opioid-induced cardioprotection. Curr Pharm Des. 2014; 20(36): 5696-5705.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.